- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 11/16 - Central respiratory analeptics
Patent holdings for IPC class A61P 11/16
Total number of patents in this class: 95
10-year publication summary
|
2
|
0
|
14
|
6
|
11
|
7
|
7
|
6
|
3
|
0
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Apnimed, Inc. (Delaware) | 55 |
5 |
| Bayer AG | 3417 |
4 |
| Raqualia Pharma Inc. | 121 |
4 |
| Amgen Inc. | 4318 |
2 |
| Takeda Pharmaceutical Company Limited | 2722 |
2 |
| University of South Florida | 1865 |
2 |
| Ambrx, Inc. | 172 |
2 |
| AMOREPACIFIC Corporation | 2878 |
2 |
| Dainippon Sumitomo Pharma Co., Ltd. | 176 |
2 |
| Elanco US Inc. | 725 |
2 |
| Jado Technologies GmbH | 5 |
2 |
| Monash University | 725 |
2 |
| Nippon Chemiphar Co., Ltd. | 226 |
2 |
| Taisho Pharmaceutical Co., Ltd. | 863 |
2 |
| Technische Universität Dresden | 558 |
2 |
| Zenith Epigenetics Ltd. | 29 |
2 |
| Insignis Therapeutics, Inc. | 8 |
2 |
| UCL Business Ltd | 642 |
2 |
| Enalare Therapeutics Inc. | 27 |
2 |
| Takasaki University of Health and Welfare | 8 |
2 |
| Other owners | 48 |